Evidence map›Paper›PMID 37946288›Full record

ArticleActa neuropathologica communications2023

Accurate digital quantification of tau pathology in progressive supranuclear palsy.

Tanrada Pansuwan, Annelies Quaegebeur, Sanne S Kaalund, Eric Hidari, Mayen Briggs, James B Rowe, Timothy Rittman

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Tanrada PansuwanDepartment of Clinical Neurosciences, Cambridge University Centre for Parkinson-Plus, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK. tp500@cam.ac.uk.ORCID 0000-0002-8433-2453
Annelies QuaegebeurDepartment of Clinical Neurosciences, Cambridge University Centre for Parkinson-Plus, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK.
Sanne S KaalundCentre for Neuroscience and Stereology, Bispebjerg University Hospital, Copenhagen, Denmark.
Eric HidariDepartment of Clinical Neurosciences, Cambridge University Centre for Parkinson-Plus, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK.
Mayen BriggsCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
James B RoweDepartment of Clinical Neurosciences, Cambridge University Centre for Parkinson-Plus, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK.
Timothy RittmanDepartment of Clinical Neurosciences, Cambridge University Centre for Parkinson-Plus, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK.
University of Cambridge · GBBispebjerg Hospital · DKCambridge University Hospitals NHS Foundation Trust · GBMRC Cognition and Brain Sciences Unit · GB

Funding

Medical Research Council MC_UU_00030/14Medical Research Council MR/T033371/1Wellcome TrustWellcome Trust 103838Wellcome Trust 220258
6 · The paper itself

Abstract

The development of novel treatments for Progressive Supranuclear Palsy (PSP) is hindered by a knowledge gap of the impact of neurodegenerative neuropathology on brain structure and function. The current standard practice for measuring postmortem tau histology is semi-quantitative assessment, which is prone to inter-rater variability, time-consuming and difficult to scale. We developed and optimized a tau aggregate type-specific quantification pipeline for cortical and subcortical regions, in human brain donors with PSP. We quantified 4 tau objects ('neurofibrillary tangles', 'coiled bodies', 'tufted astrocytes', and 'tau fragments') using a probabilistic random forest machine learning classifier. The tau pipeline achieved high classification performance (F1-score > 0.90), comparable to neuropathologist inter-rater reliability in the held-out test set. Using 240 AT8 slides from 32 postmortem brains, the tau burden was correlated against the PSP pathology staging scheme using Spearman's rank correlation. We assessed whether clinical severity (PSP rating scale, PSPRS) score reflects neuropathological severity inferred from PSP stage and tau burden using Bayesian linear mixed regression. Tufted astrocyte density in cortical regions and coiled body density in subcortical regions showed the highest correlation to PSP stage (r = 0.62 and r = 0.38, respectively). Using traditional manual staging, only PSP patients in stage 6, not earlier stages, had significantly higher clinical severity than stage 2. Cortical tau density and neurofibrillary tangle density in subcortical regions correlated with clinical severity. Overall, our data indicate the potential for highly accurate digital tau aggregate type-specific quantification for neurodegenerative tauopathies; and the importance of studying tau aggregate type-specific burden in different brain regions as opposed to overall tau, to gain insights into the pathogenesis and progression of tauopathies.

Indexed as

Supranuclear Palsy, ProgressiveTauopathiesBayes TheoremBrainHumansReproducibility of Resultstau Proteinstau ProteinsDigital pathologyMachine learningNeurodegenerative diseasesPSPRandom forest

Identifiers

PMID37946288
PMCPMC10634011
OpenAlexW4388532435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.